UBL5 Gene Therapy Nanoparticles for Mitochondrial Stress
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics are lacking for diseases associated with mitochondrial stress, which leads to energy depletion, free radical production, and inflammatory responses, affecting conditions such as fatty liver disease, obesity, diabetes, and rare genetic diseases like Leptin Receptor Deficiency and Fanconi anemia.
Innovation Solution
Nanoparticles containing nucleic acid molecules encoding human ubiquitin-like protein 5 (UBL5) or other proteins, along with CD44 targeting peptides, are used to increase protein expression in cells, thereby addressing mitochondrial stress and related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutics are used for mitochondrial stress-related diseases, then existing treatment options are limited, but no effective therapeutics are available to address the core disease mechanism
Solution Approach 1:
The patent uses nanoparticles as intermediary carriers to deliver therapeutic proteins (UBL5, SOD2, FXN, etc.) directly to cells with mitochondrial stress. These nanoparticles mediate the delivery process, enabling targeted therapy that was previously unavailable. The nanoparticles contain the therapeutic proteins and facilitate their entry into affected cells, addressing the core disease mechanism of mitochondrial stress.
2Reliability
If nanoparticle delivery systems are used to increase protein expression in cells, then therapeutic effectiveness is improved, but device complexity increases
Solution Approach 1:
The nanoparticle delivery system is designed to be universal and multi-functional. It can deliver multiple different therapeutic proteins (UBL5, SOD2, FXN, NDUFAF3, UQCRC2, CEP295, CDC45) using the same nanoparticle platform. The nanoparticles have universal targeting capabilities and can be applied to treat various mitochondrial stress-related diseases including fatty liver disease, obesity, diabetes, and rare genetic diseases, reducing the need for disease-specific delivery systems.
3Use of energy by moving object
If mitochondrial stress is left untreated, then energy depletion and free radical production continue, but inflammatory response and tissue damage worsen
Solution Approach 1:
The patent addresses the harmful effects of mitochondrial stress by introducing therapeutic proteins that convert the harmful state into a beneficial one. UBL5, SOD2, and other therapeutic proteins directly counteract free radical production and reduce inflammatory responses. The therapy transforms the harmful mitochondrial stress condition into improved cellular function by enhancing mitochondrial performance and reducing oxidative damage.
Data Source
AI summary
Nanoparticles comprising a nucleic acid molecule encoding human ubiquitin-like protein 5 (UBL5) or human UBL5 protein are provided. Methods of treating a disease, disorder or condition characterized by mitochondrial stress are provided. Expression vectors, nucleic acid molecules, peptides, pharmaceutical compositions and methods of identifying a gene for use in gene therapy, targeting an agent to a CD44 expressing cell and producing a therapeutic nanoparticle are also provided.